HOME >> MEDICINE >> NEWS
Targeting mutant B-Raf protein reduces melanoma development

HERSHEY, PA- Researchers at Penn State College of Medicine have identified the mechanism by which the most mutated gene in melanoma, called v599EB-Raf, aids melanoma tumor development demonstrating its importance as a therapeutic target.

"Our studies suggest that using therapies to target and inhibit the function of mutant v599EB-Raf protein could prevent the spread of melanoma and halt tumor growth for those melanomas containing the B-Raf mutation," said Gavin P. Robertson, Ph.D., assistant professor of pharmacology, pathology, and dermatology, Penn State College of Medicine, Penn State Milton S. Hershey Medical Center. "With cases of melanoma increasing at about 4 percent per year and no effective treatments available for advanced-stage disease, it's imperative that we continue to look for important proteins that could be targeted therapeutically. Studies like this one that identify how inhibiting important melanoma regulating proteins reduce melanoma development will lead to a better understanding of the disease, and thus, the development of more effective long-term treatment options for patients."

The study, titled "Mutant V599EB-Raf Regulates Growth and Vascular Development of Malignant Melanoma Tumors," appeared in the March 15, 2005, issue of Cancer Research.

The job of normal non-mutated B-Raf is to relay signals from the cell membrane, which is the boundary of the cell receiving the signals, to the nucleus, which contains genetic material and controls many of the cell's activities. B-Raf is one member of the chain that relays signals playing an important role in cell signaling. The protein is usually only active when needed to relay signals.

In contrast, mutant B-Raf is active all the time, which disrupts the chain's normal function. Previous studies have shown B-Raf is the most mutated gene in melanomas, present in about 60 percent of human melanomas, but the role mutant B-Raf plays in causing melanoma tumors remained unkn
'"/>

Contact: Valerie Gliem
vgliem@psu.edu
814-865-9481
Penn State
22-Mar-2005


Page: 1 2 3

Related medicine news :

1. Jefferson and Molecular Targeting Technologies, Inc. scientists create vaccine for wildlife rabies
2. Targeting cell fusion as possible way to repair organs, deliver cancer vaccines
3. Targeting bone metastasis and hypercalcemia
4. Effective Obesity Treatment Likely To Require Targeting Of Multiple Weight Control Systems
5. Myosin mutant points to human origins
6. Mechanism of RNA recoding: New twists in brain protein production
7. Epstein-Barr virus protein crucial to its role in blood cancers
8. Neuronal death and processing of Tau protein in Alzheimers disease
9. CK2 protein sustains colon cancer cells by sabotaging ability to commit suicide
10. Brain synapse formation linked to proteins, Stanford study finds
11. Stat5 protein inhibits spread of breast cancer cells

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/5/2020)... Calif. (PRWEB) , ... August 05, 2020 , ... ... America’s healthcare system has repeatedly risen to unprecedented challenges. Regardless of the obstacle ... such as personal protective equipment (PPE) and the cancellation or postponement of all ...
(Date:8/5/2020)... ... 2020 , ... The Veterinary Cooperative named Ginni Hamele, an ... purchasing Cooperative in the United States. , Hamele has spent the last nine ... and experience in the animal health industry. In her most recent position for ...
(Date:8/5/2020)... ... 2020 , ... Total Spectrum, a company of behavioral clinicians ... is delighted to announce the grand opening of their new ABA learning ... Spectrum now proudly serves ten different locations across the Midwest. The staff of ...
(Date:8/3/2020)... N.J. (PRWEB) , ... August 03, 2020 , ... ... in Florida will launch its Suite360:Mental Health and Prevention program district-wide, developed to ... and Child Trafficking Prevention. , Florida schools and districts must provide their ...
(Date:8/3/2020)... ... August 03, 2020 , ... ... the first patients with first-line advanced pancreatic cancer in a phase 2 study ... of 9-ING-41, (NCT03678883, EudraCT#:2018-003739-32). 9-ING-41 is Actuate’s proprietary small molecule glycogen synthase ...
Breaking Medicine News(10 mins):
(Date:8/5/2020)... Ohio (PRWEB) , ... August 04, 2020 , ... ... loved ones, has announced the Best Rehab Facilities in Akron, Ohio for 2020. The ... accompanying services and more. , According to recent studies , drug overdose ...
(Date:8/5/2020)... ... ... Fifty six percent of older adults think we need to invest more in Medicare ... according to a new survey by The Senior Citizens League (TSCL). “Boosting funding ... says Mary Johnson, a Medicare, and Social Security policy analyst for The Senior Citizens ...
(Date:8/5/2020)... Va. (PRWEB) , ... August ... ... Cleaning and Disinfectant Programs: , Best Practices During COVID-19, An FDAnews Webinar, ... The task of maintaining a controlled cleanroom is never simple and COVID-19 ...
Breaking Medicine Technology:
Cached News: